LP171382-7
Abciximab
Active
Description
Abciximab is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.
Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage.
Thrombocytopenia is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for seven days after initial drug administration.
Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
Source: Wikipedia, Abciximab
Basic Part Properties
- Part Display Name
- Abciximab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2012-12-19
- Construct for LOINC Short Name
- Abciximab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP171382-7
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| zh-CN | Chinese (China) | 阿昔单抗 Synonyms: 阿西单抗; |
| es-ES | Spanish (Spain) | Abciximab |
| it-IT | Italian (Italy) | Abciximab |
| tr-TR | Turkish (Turkey) | Abciximab |
| ru-RU | Russian (Russian Federation) | Абциксимаб |
| nl-NL | Dutch (Netherlands) | abciximab |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright